GlassScriptPhysician profile
Brittany A Little
NPI 1093072985
$11,884.24
in general payments reported to CMS, 2019-2025
34 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,544 · 2022: $3,201 · 2023: $3,008 · 2024: $3,016 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,639 · Consulting Fee: $400 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,639.25 |
| Consulting Fee | $400.00 |
| Education | $100.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,614.98 | 2021-2024 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,585.66 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Mallinckrodt Hospital Products INC. | $1,183.04 | 2021-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $968.03 | 2021-2023 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $781.45 | 2021-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $683.15 | 2021-2024 | |
| United Therapeutics Corporation | $622.28 | 2021-2024 | Tyvaso, Remodulin, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $548.24 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $531.45 | 2021-2024 | Dupixent |
| Jazz Pharmaceuticals INC. | $400.44 | 2021-2025 | |
| Mylan Specialty L.P. | $370.63 | 2022-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $357.50 | 2021-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $327.31 | 2021-2024 | Glassia |
| Abbvie INC. | $300.51 | 2021 | |
| Baxter Healthcare | $223.13 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $193.43 | 2021-2023 | Xolair |
| Insmed, INC. | $162.43 | 2021-2024 | Arikayce |
| Axsome Therapeutics, INC. | $153.23 | 2022-2023 | Sunosi |
| Pfizer INC. | $142.54 | 2022-2024 | |
| Inspire Medical Systems, INC. | $109.87 | 2023 | Inspire |
| Electromed, INC. | $91.24 | 2022-2025 | Smartvest |
| E.R. Squibb & Sons, L.L.C. | $84.12 | 2021-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $83.42 | 2023-2024 | Zerbaxa, Recarbrio |
| Amgen INC. | $72.40 | 2022-2024 | Tezspire |
| Advanced Respiratory, INC | $68.64 | 2021 | |
| Ani Pharmaceuticals, INC. | $67.78 | 2024 | Purified Cortrophin Gel |
| 3b Medical, INC. | $41.70 | 2024 | Luna |
| Stryker Corporation | $32.90 | 2024 | Neptune |
| Philips North America LLC | $18.51 | 2021 | |
| Mayne Pharma Commercial LLC | $18.34 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.55 | 2024 | Nuzyra |
| Gilead Sciences, INC. | $13.49 | 2021 | |
| Nabriva Therapeutics, Plc | $13.32 | 2021 | |
| Breas Medical, INC. | $4.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.